预约演示

更新于：2026-06-20

Haloperidol

氟哌啶醇

更新于：2026-06-20

概要

基本信息

药物类型

小分子化药

别名

HAL、Haloperidol (JP17/USP/INN)、HPD

+ [8]

靶点

DRDs

作用方式

激动剂

作用机制

DRDs激动剂(多巴胺受体家族激动剂)

治疗领域

神经系统疾病遗传病与畸形

在研适应症

Tourette 综合征躁郁症精神分裂症

非在研适应症-

原研机构

Janssen Pharmaceutica NV

在研机构

精华制药集团股份有限公司

Sagent Pharmaceuticals, Inc.

Sumitomo Pharma Co., Ltd.

非在研机构

Ortho-McNeil Pharmaceutical LLC

权益机构

Clinigen Ltd.

Essential Pharmaceuticals LLC

Moksha8 Pharmaceuticals, Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

日本 (1964-10-24),

躁郁症精神分裂症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C21H23ClFNO2

InChIKeyLNEPOXFFQSENCJ-UHFFFAOYSA-N

CAS号52-86-8

关联

192

项与氟哌啶醇相关的临床试验

JPRN-jRCT1030260137

/ Not yet recruitingN/AIIT

An Observational Study of Changes in Neurological Symptoms and Functional Impairments in Patients Receiving Gait Training Using the HAL Lower Limb Type for Self-Support and Related Devices, Following Treatment with Autologous Bone Marrow-Derived Mesenchymal Stem Cells (Stemirac inj.) (SHINE Study)

开始日期2026-05-18

申办/合作机构-

ChiCTR2600122652

/ SuspendedN/AIIT

Biased μ-opioid receptor agonist tegileridine for postoperative analgesia after gynecologic laparoscopy or abdominal surgery: a prospective, double-blind, randomized controlled trial

开始日期2026-05-01

申办/合作机构

江西省妇幼保健院

ChiCTR2600121757

/ Not yet recruitingN/AIIT

The half-maximal effective concentration of cyclobutanol TCI in inhibiting cardiovascular responses during double-lumen endotracheal intubation when combined with sufentanil and remimazolam

开始日期2026-04-03

申办/合作机构-

100 项与氟哌啶醇相关的临床结果

登录后查看更多信息

100 项与氟哌啶醇相关的转化医学

登录后查看更多信息

100 项与氟哌啶醇相关的专利（医药）

登录后查看更多信息

20,166

项与氟哌啶醇相关的文献（医药）

2026-12-01·MOLECULAR BIOLOGY REPORTS

Neuronal deletion of PDE7A averts morphine-induced behavioral plasticity and impairs downstream AKT signaling

Article

作者: Tan, Zhen ; He, Kaiwu ; Li, Axiang ; Gao, Ruyan ; Liu, Zizhen ; Li, Shupeng ; Zheng, Chengyou ; Hao, Liangliang ; Ali, Tahir ; Li, Tao

BACKGROUND:

Phosphodiesterase 7 A (PDE7A) is a key regulator of cyclic adenosine monophosphate (cAMP) signaling, expressed prominently in brain regions associated with reward and addiction. Despite its strategic localization within reward-related neurocircuitry, the functional contribution of PDE7A to substance use disorders remains poorly defined.

METHODS:

We investigated the role of PDE7A in morphine-induced behavioral plasticity using a combination of genetic deletion (Nestin-Cre-mediated neuronal PDE7A knockout) and pharmacological inhibition (BRL-50481) in male C57BL/6J mice (8-10 weeks of age). Behavioral assessments included conditioned place preference (CPP) and locomotor sensitization. Biochemical analyses (ELISA, Western blotting, co-immunoprecipitation) were performed on striatal tissue to assess dopamine levels, cAMP levels, and signaling pathways (AKT/GSK3β, D2R-β-arrestin2 complex).

RESULTS:

Mice with neuronal PDE7A deficiency failed to develop morphine-induced CPP, highlighting a critical requirement for PDE7A in drug-associated memory formation. Consistently, administration of the PDE7 inhibitor BRL-50,481 (10 mg/kg, i.p.) significantly disrupted established drug memories and attenuated morphine-induced behavioral sensitization in wild-type mice. Mechanistically, PDE7A deletion led to a hyper-dopaminergic state in the striatum, characterized by elevated dopamine levels and D1 receptor expression, yet a paradoxical impairment in downstream signaling. Specifically, the behavioral effects of PDE7 inhibition were reversed by the D2 receptor antagonist haloperidol and the AKT inhibitor oridonin, suggesting a reliance on the D2R-AKT-GSK3β axis. Biochemical analyses further revealed that PDE7A deficiency suppresses the AKT/GSK3β signaling pathway, a defect validated through pharmacological manipulation of PDE7, D2R, and AKT.

CONCLUSION:

Collectively, these findings identify PDE7A as a pivotal modulator of morphine-induced addiction and suggest that targeting the PDE7A-D2R-AKT signaling cascade represents a novel therapeutic strategy for managing substance use disorders.

2026-10-01·PHYSIOLOGY & BEHAVIOR

Early adult-onset undernutrition drives duration-dependent changes in locomotion, exploration and pain sensitivity in rats

Article

作者: Abboussi, Oualid ; Hassab, Zineb ; Alamy, Meryem ; Ahami, Ahmed Omar Touhami ; Taghzouti, Khalid ; Hassab, Safae

Controlled dietary restriction, including calorie restriction and undernutrition, can modulate behavior and brain function; however, the effects of undernutrition initiated in adulthood and maintained over prolonged periods remain poorly understood. This study investigated how the duration of early adult-onset undernutrition differentially affects locomotor and exploratory behavior, responsiveness to dopaminergic blockade, and nociceptive sensitivity in rats. Starting at two months of age, animals were maintained at approximately 80 % of control body weight for 4, 25, and 32 weeks. Locomotor and exploratory activity were assessed in the open-field test. Dopaminergic responsiveness was evaluated using the D₂ receptor antagonist haloperidol, and nociceptive sensitivity was measured using the tail flick test after short- and long-term undernutrition. Undernourished rats exhibited domain- and duration-specific behavioral adaptations. Locomotor speed and distance increased early without a parallel rise in crossings, whereas crossings and exploratory rearing increased only after prolonged undernutrition. This dissociation became particularly evident under dopaminergic blockade: while haloperidol robustly suppressed locomotion at all stages, its inhibitory impact on exploratory behavior was diminished after prolonged undernutrition, consistent with selective adaptations in motivational and dopaminergic systems. In contrast, tail-flick latencies were reduced from early time points and remained stable thereafter, indicating an early and sustained increase in nociceptive sensitivity. Together, these findings demonstrate that early adult-onset undernutrition induces distinct temporal adaptations across behavioral domains, highlighting differential sensitivity of pain-related and motivational circuits to chronic energetic stress and the role of dopaminergic systems in shaping brain responses to prolonged undernutrition.

2026-08-01·BRAIN BEHAVIOR AND IMMUNITY

Clozapine-induced human microglial exosomes impair neurites and cognition

Article

作者: Thomas, Adam ; Hewitt, Kyle ; Zheng, Peng ; Huang, Xu-Feng ; Nagaratnam, Nathan

BACKGROUND:

Clozapine is the most effective treatment for treatment-resistant schizophrenia but has been linked to cognitive impairment and brain volume reductions. The potential mechanisms underlying these effects remain unclear. Microglial exosomes, which carry microRNAs (miRNAs) and other cargo, act as immune-neuron communication vectors capable of modulating neuronal function and cognition.

METHODS:

We compared cognitive performance and inflammatory markers across clozapine-treated individuals, haloperidol-treated individuals, and healthy controls. Human microglial cells were treated with clozapine and assessed for phenotypic changes and exosome production. Exosomes from control and clozapine-treated microglia were applied to neuroblastoma cells and primary murine cortical neurons to assess neurite outgrowth and brain-derived neurotrophic factor (BDNF) expression. C. elegans were exposed to exosomes and evaluated for lifespan, healthspan markers, and cognitive function via olfactory associative learning assays. Exosomal miRNA cargo was characterized by small RNA sequencing.

RESULTS:

Clozapine-treated individuals exhibited elevated systemic inflammatory markers and lower cognitive performance compared with healthy controls. Clozapine altered microglial morphology, reduced proliferation and migration, and significantly increased exosome production. Small RNA sequencing identified six dysregulated miRNAs in clozapine-induced microglial exosomes, including upregulation of miR-34a-5p. Exposure of neurons to clozapine-induced exosomes reduced neurite length, branch points, and BDNF expression. In C. elegans, clozapine-induced exosomes reduced lifespan and severely impaired learning and short-term memory.

CONCLUSIONS:

These findings identify a neuroimmune exosomal pathway through which clozapine-exposed microglia can impair neuronal structure and cognition, associated with dysregulated miRNA cargo. This work provides a framework linking microglial immune signalling, extracellular vesicle biology, and cognitive vulnerability during clozapine exposure.

177

项与氟哌啶醇相关的新闻（医药）

2026-06-19

·allsci.com

Teva files Emalex’s ecopipam with US FDA for first approval as Tourette’s therapy

Teva Pharmaceutical Industries (NYSE: TEVA) has submitted a New Drug Application (NDA) to the US FDA for ecopipam, an investigational selective dopamine D1 receptor antagonist, seeking approval for the treatment of pediatric Tourette syndrome. If approved, ecopipam would represent the first new FDA-authorized therapy for pediatric tic disorder in more than a decade and the first agent in clinical use to target the D1 receptor subtype in this indication. The filing arrives weeks after Teva closed its acquisition of Emalex Biosciences, the Chicago-based company that developed ecopipam through Phase III, in a deal valued at up to USD 900 million. The NDA is a standard submission seeking approval for ecopipam in pediatric patients with Tourette syndrome, the company said. Ecopipam has previously received both Orphan Drug Designation and Fast Track Designation from the FDA for this indication. The Orphan Drug Designation reflects the patient population of fewer than 200,000 in the US, and the Fast Track Designation is intended to facilitate a more expedited review process. No PDUFA target action date has yet been disclosed, as FDA acceptance of the filing has not been confirmed. The NDA is supported by Phase III data published in JAMA Neurology in May 2026, which reported results from a randomized, placebo-controlled withdrawal study in pediatric patients. The trial enrolled 216 participants, including 167 children and adolescents, who received open-label ecopipam for 12 weeks. Those who achieved a clinical response were then randomized to continue ecopipam or switch to placebo for a further 12 weeks. The primary efficacy endpoint was time to relapse, measured using the Yale Global Tic Severity Scale Total Tic Score (YGTSS-TTS). The study demonstrated a statistically significant benefit for ecopipam over placebo in the pediatric population, with a reported p-value of 0.008. Continued ecopipam was associated with a 50% reduction in relapse risk compared with placebo, the company said. The safety profile was described as generally well tolerated; the most frequently reported adverse events in the ecopipam arm included somnolence (11.1%), anxiety (9.7%), headache (9.7%), insomnia (8.8%), tic (7.9%), and fatigue (6.5%). Ecopipam selectively blocks the dopamine D1 receptor family, which includes the D1 and D5 subtypes. This mechanism is pharmacologically distinct from all currently approved Tourette syndrome medications, which act primarily on D2 receptors or, in the case of vesicular monoamine transporter 2 (VMAT2) inhibitors, through broader dopamine depletion. D1 receptor hypersensitivity has been hypothesized to contribute to the repetitive and compulsive behaviors characteristic of Tourette syndrome, providing the scientific rationale for D1 antagonism as a therapeutic strategy. The three agents currently holding FDA approval for tic suppression in Tourette syndrome — haloperidol (Haldol), pimozide (Orap), and aripiprazole (Abilify) — are antipsychotics originally developed for schizophrenia and are associated with adverse effects including weight gain, sedation, and in rare cases tardive dyskinesia. Teva’s own deutetrabenazine (Austedo), a VMAT2 inhibitor approved for tardive dyskinesia and Huntington’s disease chorea, is used off-label for tics but does not carry a Tourette syndrome label. Axsome Therapeutics (Nasdaq: AXSM) acquired balipodect, a selective PDE10A inhibitor with a distinct mechanism, from Takeda in April 2026 and has stated plans to develop it in Tourette syndrome, though that program remains in early-stage planning. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Copyright © 2026. AllSci Corp. All rights reserved.

临床3期临床结果孤儿药快速通道上市批准

2026-06-16

·肿瘤界

阿片类药物癌痛治疗：不良反应管理与风险防控方案

点击蓝字关注我们疼痛是肿瘤患者最常见和最令人痛苦的症状之一，与肿瘤患者的诊断、治疗、生活质量和生存期密切相关。目前，阿片类药物是临床控制中重度癌痛的一线核心用药，也是落实规范化癌痛管理、实现有效镇痛的关键手段，在临床中应用广泛。但阿片类药物存在明确用药风险，可引发恶心呕吐、瘙痒、尿潴留、过度镇静等不良反应。其中药物性便秘无法自行缓解，呼吸抑制、重度谵妄可危及生命。长期用药还易诱发药物依赖、成瘾及阿片类物质使用障碍，提升患者不良预后风险。 "肿瘤界"系统梳理阿片类药物常见不良反应的处理方案与风险防控策略，为临床安全、规范开展癌痛镇痛治疗提供参考。阿片类药物治疗癌痛不良反应管理阿片类药物不良反应（adverse drug reaction，ADR）的管理是癌痛整体治疗和全程管理的重要组成部分，需及时评估和治疗。 1. 阿片药物相关便秘（opioid induced constipation，OIC）（1）保证足够膳食纤维和液体量的摄入；刺激性泻药（番泻叶2~8片/d）或聚乙二醇溶于水（17g/8盎司，约240mL）口服可预防。（2）新近出现便秘，建议联合使用辅助药物来减少阿片类药物的剂量。（3）如果便秘持续，可口服乳果糖（15~45mL/d）、麻仁润肠丸（1~2丸、2次/d）或聚乙二醇钠钾散（1包，2~3次/d）。（4）高危患者（如原有便秘病史、OIC等）轮替为羟考酮-纳洛酮复合制剂可减少便秘的发生或缓解便秘。（5）难治性便秘患者鞘内给药或通过微创镇痛治疗可减少甚至逐步停用全身阿片类药物。 2. 恶心、呕吐（1）一线药物：口服甲氧氯普胺（10~15mg，4次/d）、丙氯拉嗪（10mg/6小时，按需给药）或氟哌啶醇（0.5~1mg/6~8h，按需给药）。（2）可替代药物：口服昂丹司琼（8mg，3次/d）或格拉司琼（1mg，2次/d）、奥氮平（2.5~5mg/睡前）、地塞米松等。（3）如恶心持续1周以上，须重新评估、排除其他原因，不能缓解者可考虑阿片类药物轮替、鞘内给药或其他微创镇痛治疗以减少全身阿片类药物剂量。（4）呕吐高危患者（如首次使用阿片类药物、既往呕吐史）可预防性使用昂丹司琼、格拉司琼等。 3. 瘙痒（1）瘙痒伴有皮疹、荨麻疹或呼吸短促，应考虑阿片药物过敏，重新选择另一种阿片类药物。（2）药物治疗：西替利嗪（5~10mg/d，口服或静注）、苯海拉明（25~50mg/6h，口服或静注）、异丙嗪（25mg/12h，肌注）。（3）药物治疗失败考虑阿片类药物轮替；或小剂量纳洛酮持续输注（0.25~1µg/kg/h），缓解瘙痒同时不会降低阿片类药物镇痛作用。 4. 谵妄（1）排除其他可能导致谵妄的因素（如感染、高钙血症、中枢神经系统异常、疾病转移、其他精神类药物或无法控制的疼痛等）。（2）降低阿片类药物剂量或轮替使用另一种阿片类药物。（3）药物治疗：氟哌啶醇（0.5~2mg/4~6h）、奥氮平（2.5~5mg/6~8h，口服），或利培酮（0.25~0.5mg，1~2次/d，肌注）。 5. 尿潴留（1）诱导排尿：流水诱导、膀胱按摩或下腹部（膀胱区）热敷等。（2）药物治疗：坦索罗辛（0.2mg，1次/d，口服）。（3）导尿或留置导尿管（2~3天），如不能缓解需重新评估，排除其他因素或专科处理。 6. 镇静建议采用帕赛罗阿片类药物相关镇静量表（pasero opioid-induced sedation scale，POSS）评估阿片类药物引起的镇静水平（表），并依此调整阿片类药物剂量。表：POSS阿片类药物镇静量表及处理镇静等级处理方式 S. 睡眠（易于唤醒）无需处理，阿片药物正常使用 1. 清醒且警觉无需处理，阿片药物正常使用 2. 略微困倦（易于唤醒）无需处理，阿片药物正常使用 3. 经常困倦可被唤醒，谈话间昏沉入睡阿片类药物剂量减少25%~50%，进一步风险评估；如无禁忌证，可以使用无镇静作用的非阿片类药物（例如，对乙酰氨基酚或非甾体类抗炎药）；密切监控镇静水平，防止呼吸抑制，直至POSS<3且保障充分呼吸。 4. 嗜睡对言语或身体刺激反应较小或无反应停止使用阿片类药物，必要时考虑给患者使用纳洛酮；密切监控呼吸抑制和镇静水平，直至POSS<3且保障充分呼吸。 7. 呼吸抑制（1）镇静通常先于呼吸抑制发生，镇静水平进行性加重时需警惕呼吸抑制的发生。呼吸频率<10次/min，可能是呼吸抑制的早期体征。（2）频率减慢是阿片类药物呼吸抑制的特征，如呼吸频率<8次/min需立即处理，包括：减少阿片类药物剂量、延长其给药间隔或暂停使用。密切监测氧饱和（SpO2），如SpO2<90%应予鼻导管或面罩吸氧，必要时无创呼吸支持，直至呼吸状态改善。如患者病情不稳或反应迟钝，可考虑纳洛酮拮抗（0.4mg/10mL的纳洛酮1~2mL/30~60s静注，直至症状改善）。如10分钟内对纳洛酮无反应，且纳洛酮总剂量达到1mg，应考虑导致神经系统状态变化的其他原因。表：癌痛全程管理常用阿片类药物的特点及注意事项阿片类药物使用中风险与风险缓解策略 1. 阿片依赖与成瘾阿片类药物依赖包括躯体依赖和精神依赖。前者主要表现为“阿片戒断反应”，当阿片类药物骤然停药/减量，机体会出现焦虑、易怒、寒战、出汗、关节痛、流泪、恶心、呕吐、腹部绞痛、腹泻等戒断症状。精神依赖即“成瘾”，表现为用药失去控制、强迫性使用，尽管受到伤害，患者仍继续和渴望使用药物。精神依赖将严重损害生活质量。 2. 阿片类药物滥用药物滥用指为了获得理想的精神或生理效应，有意、非治疗性地使用药物，即使只用药1次。在长期使用阿片类药物患者中，阿片类药物滥用的发生率在21%~29%。滥用可能导致阿片成瘾。 3. 阿片样物质使用障碍阿片样物质使用障碍（Opioid use disorder，OUD）被认为是一组与阿片类药物相关的认知、行为和心理症状，提示个体存在明显的与阿片类药物相关问题时仍继续使用。长期使用阿片类药物的癌痛患者中，8%~12%会出现OUD，导致长期过量使用，对免疫功能产生显著负面影响，并有可能增加肿瘤复发和死亡风险。 4. 风险缓解策略（1）评估工具选择：阿片类药物使用前，推荐使用《癌痛患者筛查及阿片类药物应用评估（screener and opioid assessment for patients with pain-revised，SOAPP-R）》和/或《阿片类药物风险评估工具（opioid risk tool，ORT）》进行评估；阿片类药物使用过程中推荐使用《阿片类药物滥用状况量表（current opioid misuse measure，COMM）》进行实时监测评估。（2）预防及处理：向患者以及家属宣教阿片类药物治疗的潜在风险和获益、合理使用与储存等。肿瘤幸存者如需长期使用阿片类药物，应尽量使用低剂量并及时随访。合并OUD的慢性癌痛患者推荐使用美沙酮、丁丙诺啡进行疼痛管理。对高风险OUD患者，应尽早转诊至疼痛科、介入科等，通过微创镇痛或介入治疗予以足够镇痛，最大限度地减少阿片类药物应用。多学科诊疗干预，通过临床姑息医学专家和精神心理专家、OUD专家、社会服务机构合作等协调治疗。推荐阅读《2026 NCCN成人癌痛指南中文版》正式发布癌痛全程管理中国专家共识（2025版）《中国临床肿瘤学会(CSCO)癌痛诊疗指南》编写启动会在济南召开声明：本文由“肿瘤界”整理与汇编，欢迎分享转载，如需使用本文内容，请务必注明出处。参考文献： 1. 中国肿瘤整合诊治指南（CACA)成人癌痛治疗_V2.0_2026 2. 中国医师协会疼痛科医师分会,国家卫生健康委能力建设和继续教育中心癌痛全程管理专家组. 癌痛全程管理中国专家共识（2025版）[J]. 中国疼痛医学杂志, 2025, (9):643-657. 编辑：Lagertha 审核：阿希雅

2026-06-11

·动脉网

阿尔茨海默病激越症状市场在预测期（2026-2036年）将以14.9%的年均复合增长率实现巨大增长 DelveInsightAgitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036)

The recent approval of Axsome Therapeutics' AUVELITY has transformed the agitation in Alzheimer's disease market. The emergence of investigational therapies, including IGC-AD1 (IGC Pharma), Masupirdine (SUVN-502) (Suven Life Sciences), EXV-801 ± Dextromethorphan (Exciva GmbH), COBENFY (KarXT; xanomeline–trospium chloride) (Bristol Myers Squibb/Karuna Therapeutics), and others, is also transforming the agitation in Alzheimer's disease treatment landscape through novel and diverse mechanisms of action. Axsome Therapeutics 公司的 AUVELITY 近期获批，已彻底改变阿尔茨海默病激越症状治疗市场。包括 IGC Pharma 的 IGC-AD1、Suven Life Sciences 的 Masupirdine（SUVN-502）、Exciva GmbH 的 EXV-801 ± 右美沙芬、Bristol Myers Squibb/Karuna Therapeutics 的 COBENFY（KarXT；昔诺美林–托吡氯铵）等在内的在研疗法的涌现，正通过新颖且多样的作用机制，重塑阿尔茨海默病激越症状的治疗格局。These advancing therapies are anticipated to broaden available treatment choices and support the ongoing evolution of the market.. 这些不断发展的疗法预计将扩大可用的治疗选择，并支持市场的持续演变。LAS VEGAS 拉斯维加斯, ，June 11, 2026 2026年6月11日/PRNewswire/ -- Recently published Agitation in Alzheimer's Disease Market Insights report includes a comprehensive understanding of current treatment practices, agitation in Alzheimer's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].. /PRNewswire/ -- 最近发布的《阿尔茨海默病激越市场洞察》报告全面分析了当前的治疗实践、阿尔茨海默病激越在研新药、各疗法的市场份额，以及2022年至2036年的当前市场规模和预测市场规模，并按主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）进行了细分。Agitation in Alzheimer's Disease Market Summary 阿尔茨海默病激越症状市场概览The market size for agitation in Alzheimer's disease was found to be 阿尔茨海默病激越症状的市场规模被发现为USD 600 million 6亿美元in the 7MM in 2025. 在2025年的7MM中。The United States accounted for the largest agitation in Alzheimer's disease treatment market size, approximately 美国在阿尔茨海默病治疗市场规模中占据最大份额，约为83% 83%of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. 占2025年七大主要市场（7MM）总市场规模的比例，并与包括欧盟四国（德国、法国、意大利和西班牙）、英国和日本在内的其他主要市场进行比较。The total number of diagnosed cases of agitation in alzheimer's in the 7MM is 在7MM中，阿尔茨海默病激越症状的确诊总病例数为~11 million 约1100万in 2025. 2025年。Leading agitation in Alzheimer's disease companies, such as 在阿尔茨海默病领域处于领先地位的公司，例如IGC Pharma, Suven Life Sciences, Exciva GmbH, Bristol Myers Squibb, Karuna Therapeutics, IGC Pharma，Suven Life Sciences，Exciva GmbH，百时美施贵宝，Karuna Therapeutics，and others, are developing new agitation in Alzheimer's disease treatment drugs that can be available in the agitation in Alzheimer's disease market in the coming years. 以及其他公司正在开发用于治疗阿尔茨海默病激越症状的新药，这些药物有望在未来几年内上市。The promising agitation in Alzheimer's disease therapies in clinical trials include 阿尔茨海默病治疗在临床试验中展现出的令人鼓舞的进展包括IGC-AD1, Masupirdine (SUVN-502), EXV-801 ± Dextromethorphan, COBENFY (KarXT; xanomeline–trospium chloride), IGC-AD1、Masupirdine（SUVN-502）、EXV-801 ± 右美沙芬、COBENFY（KarXT；卡诺美林–托哌氯铵）and others. 以及其他。Discover what is the future of the agitation in Alzheimer's disease treatment market @ 探索阿尔茨海默病治疗市场中激越症状的未来 @https://www.delveinsight.com/report-store/agitation-in-alzheimer-disease https://www.delveinsight.com/report-store/agitation-in-alzheimer-diseaseKey Factors Driving the Growth of the Agitation in Alzheimer's Disease Market 推动阿尔茨海默病激越症状市场增长的关键因素Rising Prevalence of Alzheimer's Disease: 阿尔茨海默病患病率持续上升：The increasing global burden of Alzheimer's disease is directly contributing to a larger patient pool experiencing agitation symptoms. In 2025, the total number of diagnosed cases of agitation in Alzheimer's disease in the 7MM was around 阿尔茨海默病的全球负担日益加重，直接导致出现激越症状的患者群体不断扩大。2025年，七大主要市场（7MM）中阿尔茨海默病伴发激越症状的确诊总病例数约为11 million 1100万. Among the 7MM countries, the US accounted for the highest number of diagnosed prevalent cases of Alzheimer's disease, contributing around 在七大主要市场国家中，美国确诊的阿尔茨海默病现患病例数最多，约占49% 49%, while the UK reported the lowest number of cases in 2025. ，而英国在2025年报告的病例数最少。Increasing Awareness and Early Diagnosis: 提高意识与早期诊断：Growing awareness among caregivers, physicians, and healthcare organizations is improving recognition of neuropsychiatric symptoms in Alzheimer's disease. 护理人员、医生和医疗保健机构对阿尔茨海默病神经精神症状的认识不断提高，从而改善了对这些症状的识别。Entry of Axsome Therapeutics' AUVELITY: Axsome Therapeutics公司AUVELITY的上市：In April 2026, Axsome Therapeutics secured FDA approval for AUVELITY to treat agitation associated with Alzheimer's-related dementia, making it the first oral non-antipsychotic therapy approved for this indication. The approval was backed by the Phase 3 ADVANCE-1 and ACCORD-2 trials. Previously approved in 2022 for MDD, the label expansion significantly enhances AUVELITY's therapeutic and commercial potential.. 2026年4月，Axsome Therapeutics获得美国食品药品监督管理局（FDA）批准，将AUVELITY用于治疗与阿尔茨海默病相关痴呆的激越症状，使其成为首个获批用于该适应症的口服非抗精神病药物疗法。此次批准基于ADVANCE-1和ACCORD-2两项III期临床试验的结果。AUVELITY此前于2022年获准用于治疗重度抑郁症（MDD），此次适应症扩展显著提升了其治疗价值和商业潜力。Emergence of Novel Therapies: 新疗法的涌现：The dynamics of the agitation in Alzheimer's disease market are expected to change in the coming years due to the launch of emerging therapies such as 阿尔茨海默病躁动治疗市场的动态预计将在未来几年因新兴疗法的上市而发生变化，例如IGC-AD1 IGC-AD1(IGC Pharma), (IGC Pharma),Masupirdine (SUVN-502) 马苏匹定（SUVN-502）(Suven Life Sciences), （苏文生命科学公司），EXV-801 ± Dextromethorphan EXV-801 ± 右美沙芬(Exciva GmbH), （Exciva 有限公司）COBENFY (KarXT; xanomeline–trospium chloride) COBENFY（KarXT；卡诺美林–托哌氯铵）(Bristol Myers Squibb/Karuna Therapeutics), and others. （百时美施贵宝/Karuna Therapeutics）及其他公司。Ramandeep Singh, a neurology expert at DelveInsight, said that with increasing clinical and commercial momentum, the space is poised for substantial evolution, and by 2036, COBENFY is expected to emerge as the leading revenue-generating therapy across the 7MM for this indication. DelveInsight的神经病学专家拉曼迪普·辛格（Ramandeep Singh）表示，随着临床和商业势头的不断增强，该领域有望迎来重大变革；到2036年，COBENFY预计将成为针对这一适应症在七大主要市场（7MM）中收入领先的治疗药物。Agitation in Alzheimer's Disease Market Analysis 阿尔茨海默病激越症状市场分析Despite the immense burden of disease, the treatment landscape for agitation in Alzheimer's disease has long relied more on clinical improvisation than targeted therapeutic precision. 尽管疾病负担沉重，阿尔茨海默病激越症状的治疗格局长期以来更依赖于临床上的临时应对，而非精准的靶向治疗。Real-world prescribing patterns show that atypical antipsychotics account for the majority of treatments (55.5% of prescriptions), followed by selective serotonin reuptake inhibitors (SSRIs) at 29.3% and benzodiazepines at 23.2%, all prescribed off-label for this indication. 真实世界中的处方模式显示，非典型抗精神病药物占治疗的大部分（55.5%的处方），其次是选择性5-羟色胺再摄取抑制剂（SSRIs），占29.3%，苯二氮䓬类药物占23.2%，所有这些药物均超说明书用于该适应症。Agents such as risperidone, quetiapine, olanzapine, and haloperidol have traditionally formed the backbone of management strategies, despite lacking formal approval for agitation in AD. Their widespread use has been accompanied by significant safety concerns, including sedation, falls, metabolic complications, cardiovascular risks, and notably, increased mortality among elderly patients.. 利培酮、喹硫平、奥氮平和氟哌啶醇等药物传统上构成了管理策略的核心，尽管它们尚未获得正式批准用于阿尔茨海默病（AD）相关的激越症状。这些药物的广泛使用伴随着显著的安全性担忧，包括镇静、跌倒、代谢并发症、心血管风险，以及尤为突出的老年患者死亡率增加。A major breakthrough came in 2023, when 2023年取得了一项重大突破，当时REXULTI 雷克斯蒂(brexpiprazole), jointly developed by （布瑞哌唑），由……联合开发Otsuka Pharmaceutical and Lundbeck 大冢制药和灵北制药, became the first FDA-approved therapy specifically indicated for agitation associated with Alzheimer's dementia. ，成为首个获美国食品药品监督管理局（FDA）批准、专门用于治疗阿尔茨海默病痴呆相关激越症状的疗法。Momentum in the field accelerated further in late April 2026, when 2026年4月下旬，该领域的势头进一步加速，当时Axsome Therapeutics Axsome Therapeuticssecured FDA approval for 获得美国食品药品监督管理局（FDA）批准AUVELITY 奥维利蒂(dextromethorphan hydrobromide/bupropion hydrochloride) for agitation associated with dementia due to Alzheimer's disease. The approval marked a significant milestone, making AUVELITY the first oral non-antipsychotic therapy approved for this condition. （氢溴酸右美沙芬/盐酸安非他酮）用于治疗阿尔茨海默病所致痴呆相关的激越症状。该批准标志着一个重要的里程碑，使AUVELITY成为首个获批用于此病症的口服非抗精神病疗法。The emergence of AUVELITY represents more than a single product approval; it signals an increasingly competitive and innovation-driven market. Several promising candidates are advancing through the pipeline, including AUVELITY 的问世不仅仅意味着单一产品的获批；它标志着一个竞争日益激烈、由创新驱动的市场正在形成。包括IGC-AD1 IGC-AD1(IGC Pharma), (IGC Pharma),Masupirdine (SUVN-502) 马苏吡啶（SUVN-502）(Suven Life Sciences), （苏文生命科学公司），EXV-801 ± Dextromethorphan EXV-801 ± 右美沙芬(Exciva GmbH), and （Exciva GmbH），以及COBENFY (KarXT; xanomeline–trospium chloride) COBENFY（KarXT；卡诺美林–氯化托斯比胺）from Bristol Myers Squibb/Karuna Therapeutics, among others. 来自百时美施贵宝/Karuna Therapeutics等公司。Agitation in Alzheimer's Disease Competitive Landscape 阿尔茨海默病激越症状的竞争格局Some of the agitation in Alzheimer's disease drugs under development include 正在研发中的阿尔茨海默病药物中，部分引发的争议包括IGC-AD1 IGC-AD1(IGC Pharma), (IGC Pharma),Masupirdine (SUVN-502) 马斯吡啶（SUVN-502）(Suven Life Sciences), （Suven生命科学公司），EXV-801 ± Dextromethorphan EXV-801 ± 右美沙芬(Exciva GmbH), （Exciva 有限公司），COBENFY (KarXT; xanomeline–trospium chloride) COBENFY（KarXT；卡诺美林–氯化托哌酮）(Bristol Myers Squibb/Karuna Therapeutics), and others. （百时美施贵宝/卡鲁纳治疗公司）等。IGC Pharma's IGC-AD1 (melatonin/tetrahydrocannabinol) IGC Pharma 公司的 IGC-AD1（褪黑素/四氢大麻酚）is an investigational combination therapy for agitation linked to Alzheimer's disease. By integrating THC with melatonin, the therapy is designed to influence neuroinflammatory pathways, neuronal communication, and circadian rhythm regulation, to alleviate agitation and improve behavioral outcomes in patients who currently have limited therapeutic options.. 是一种针对阿尔茨海默病相关激越症状的研究性联合疗法。该疗法通过将四氢大麻酚（THC）与褪黑素相结合，旨在影响神经炎症通路、神经元通讯以及昼夜节律调节，从而减轻激越症状并改善目前治疗选择有限的患者的行为结局。Suven Life Sciences' Masupirdine Suven生命科学公司的Masupirdine, a selective 5-HT6 receptor antagonist, represents a non-dopaminergic strategy aimed at stabilizing symptoms through serotonin pathway modulation. Its global Phase III study had reached nearly 50% enrollment by November 2025, and topline findings are expected in Q1/Q2 2027. ，一种选择性5-HT6受体拮抗剂，代表了一种通过调节血清素通路来稳定症状的非多巴胺能策略。截至2025年11月，其全球III期研究的入组率已接近50%，预计将于2027年第一季度或第二季度公布主要结果。Meanwhile, 与此同时，Bristol Myers Squibb/Karuna Therapeutics' COBENFY 百时美施贵宝/卡拉纳治疗公司的COBENFY, which has already generated significant interest in schizophrenia treatment, is being explored for agitation in Alzheimer's disease via muscarinic receptor modulation, offering a cholinergic mechanism that may also support cognitive function. 该药物已在精神分裂症治疗领域引起广泛关注，目前正通过调节毒蕈碱受体探索其在阿尔茨海默病激越症状中的应用，其胆碱能机制也可能有助于支持认知功能。Exciva GmbH's EXV-802 Exciva GmbH 的 EXV-802, an advanced Phase II/III neuroactive therapy candidate under investigation both as a standalone treatment and in combination with EXV-801 to address multiple CNS signaling pathways associated with agitation. This reflects an industry-wide move toward multi-target and combination-based therapeutic strategies intended to enhance efficacy while maintaining functional tolerability in complex neurobehavioral conditions. ，一种先进的处于II/III期临床试验阶段的神经活性疗法候选药物，正在作为单一疗法以及与EXV-801联合用药进行研究，旨在针对与激越相关的多种中枢神经系统信号通路。这反映了整个行业向多靶点和基于联合治疗的策略转变，以期在复杂的神经行为障碍中提高疗效，同时保持功能性的耐受性。In November 2024, EXV-802 also received Fast Track Designation from the US FDA for the treatment of agitation associated with Alzheimer's disease.. 2024年11月，EXV-802还获得了美国食品药品监督管理局（FDA）授予的“快速通道资格”，用于治疗与阿尔茨海默病相关的激越症状。The anticipated launch of these emerging therapies are poised to transform the agitation in Alzheimer's disease market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the agitation in Alzheimer's disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期上市将在未来几年内彻底改变阿尔茨海默病相关激越症状的治疗市场格局。随着这些前沿疗法不断成熟并获得监管批准，它们有望重塑阿尔茨海默病相关激越症状的市场格局，提供新的护理标准，并为医疗创新和经济增长带来新机遇。Discover more about which pipeline drugs could transform agitation in Alzheimer's disease treatment @ 了解更多关于哪些在研药物可能改变阿尔茨海默病激越症状的治疗 @Agitation in Alzheimer's Disease Drugs 阿尔茨海默病药物中的激越症状Recent Developments in the Agitation in Alzheimer's Disease Market 阿尔茨海默病躁动症治疗市场的最新进展In 在April 2026, Axsome Therapeutics, Inc. 2026年4月，Axsome Therapeutics公司announced that the FDA had approved AUVELITY for managing agitation linked to dementia caused by Alzheimer's disease. AUVELITY becomes the first treatment of its kind for Alzheimer's-related agitation, acting through modulation of the NMDA and sigma-1 receptors. 宣布美国食品药品监督管理局（FDA）已批准AUVELITY用于治疗阿尔茨海默病所致痴呆相关的激越症状。AUVELITY成为首款针对阿尔茨海默病相关激越症状的同类治疗药物，其作用机制为调节NMDA受体和sigma-1受体。In 在February 2026, IGC Pharma 2026年2月，IGC Pharmareported that approximately 70% of the planned enrollment in its ongoing randomized, double-blind, placebo-controlled Phase II CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease had been completed. 报告称，其正在进行的随机、双盲、安慰剂对照的II期CALMA试验（评估IGC-AD1用于阿尔茨海默病相关激越症状）的计划入组人数已完成约70%。In 在November 2025, Suven Life Sciences 2025年11月，Suven Life Sciencesreported that its global Phase III clinical trial of masupirdine (SUVN-502) achieved 50% patient enrollment for agitation in Alzheimer's disease, with the multicenter, randomized, double-blind, placebo-controlled study ongoing across North America and Europe. 报告称，其针对马斯匹尔定（SUVN-502）的全球III期临床试验在阿尔茨海默病激越症状患者入组方面已达到50%，这项多中心、随机、双盲、安慰剂对照研究正在北美和欧洲持续进行。What is Agitation in Alzheimer's Disease? 什么是阿尔茨海默病中的激越症状？Agitation in Alzheimer's disease refers to a cluster of behavioral and emotional symptoms characterized by excessive restlessness, irritability, aggression, emotional distress, or inappropriate verbal and physical behaviors that occur in individuals with Alzheimer's-related dementia. It is one of the most common neuropsychiatric manifestations of the disease and can include pacing, shouting, resistance to care, wandering, verbal outbursts, or physical aggression. 阿尔茨海默病中的激越症状是指在与阿尔茨海默病相关的痴呆患者中出现的一组行为和情绪症状，其特征为过度坐立不安、易怒、攻击性、情绪痛苦或不适当的言语和身体行为。它是该疾病最常见的神经精神表现之一，可包括踱步、喊叫、抗拒护理、游荡、言语爆发或身体攻击。Agitation often arises from a combination of cognitive decline, impaired communication, environmental stressors, unmet physical or emotional needs, and underlying neurobiological changes associated with disease progression. These symptoms can significantly impair quality of life, increase caregiver burden, accelerate institutionalization, and complicate disease management, making agitation a major clinical challenge in Alzheimer's disease care.. 激越症状往往由认知功能衰退、沟通障碍、环境压力源、未得到满足的生理或情感需求，以及与疾病进展相关的潜在神经生物学变化共同引发。这些症状会显著降低患者的生活质量，加重照护者负担，加速机构化照护进程，并使疾病管理复杂化，因此激越成为阿尔茨海默病照护中的一大临床挑战。Agitation in Alzheimer's Disease Epidemiology Segmentation 阿尔茨海默病躁动症状的流行病学细分The agitation in Alzheimer's disease epidemiology section provides insights into the historical and current agitation in Alzheimer's disease patient pool and forecasted trends for the leading markets. According to DelveInsight's estimates, in the United States, diagnosed cases of agitation in Alzheimer's disease are predominantly made up of females, accounting for . 阿尔茨海默病流行病学章节中的激越症状部分提供了对阿尔茨海默病患者群体中历史及当前激越症状状况的洞察，并预测了主要市场的发展趋势。根据 DelveInsight 的估算，在美国，确诊的阿尔茨海默病激越症状病例主要以女性为主，占比为。~3 million 约300万cases in 2025. 2025年的案例。The agitation in Alzheimer's disease treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into: 《阿尔茨海默病治疗市场躁动报告》提供了2022–2036年研究期间主要市场的流行病学分析，细分如下：Total Diagnosed Prevalent Cases of Alzheimer's Disease. 阿尔茨海默病确诊患病总病例数。Total Diagnosed Prevalent Cases of Agitation in Alzheimer's disease. 阿尔茨海默病中激越症状的确诊总患病人数Gender-specific Diagnosed Prevalent Cases of Agitation in Alzheimer's disease. 阿尔茨海默病中激越症状的性别特异性诊断患病病例数Age-specific Diagnosed Prevalent Cases of Agitation in Alzheimer's disease. 阿尔茨海默病中躁动症状的年龄别确诊患病病例数Total Treated Cases of Agitation in Alzheimer's Disease 阿尔茨海默病激越症状的总治疗病例数Agitation in Alzheimer's Disease Market Report Metrics 阿尔茨海默病激越症状市场报告指标Details 详情Study Period 研究期间2022–2036 2022–2036Coverage 覆盖范围7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 700万[美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]。Agitation in Alzheimer's Disease Market CAGR 阿尔茨海默病躁动症市场复合年增长率14.9% 14.9%Agitation in Alzheimer's Disease Market Size in 2025 2025年阿尔茨海默病激越症状治疗市场规模USD 600 Million 6亿美元Key Agitation in Alzheimer's Disease Companies 阿尔茨海默病领域主要企业的激越症状研究IGC Pharma, Suven Life Sciences, Exciva GmbH, Bristol Myers Squibb, Karuna Therapeutics, Otsuka Pharmaceutical, Lundbeck, Axsome Therapeutics, and others IGC Pharma、Suven Life Sciences、Exciva GmbH、百时美施贵宝、Karuna Therapeutics、大冢制药、灵北制药、Axsome Therapeutics 等Key Agitation in Alzheimer's Disease Therapies 阿尔茨海默病治疗中的关键激越症状IGC-AD1, Masupirdine (SUVN-502), EXV-801 ± Dextromethorphan, COBENFY (KarXT; xanomeline–trospium chloride), REXULTI, AUVELITY, and others IGC-AD1、Masupirdine（SUVN-502）、EXV-801 ± 右美沙芬、COBENFY（KarXT；卡诺美林–氯化托斯品）、REXULTI、AUVELITY 等Scope of the 范围Agitation in Alzheimer's Disease 阿尔茨海默病中的激越症状Market Report 市场报告Agitation in Alzheimer's Disease Patient Population Forecast 阿尔茨海默病患者人群激越症状预测Agitation in Alzheimer's Disease Therapeutics Market Size 阿尔茨海默病躁动治疗市场规模Agitation in Alzheimer's Disease Pipeline Analysis 阿尔茨海默病激越症状在研药物管线分析Agitation in Alzheimer's Disease Market Size and Trends 阿尔茨海默病激越症状市场规模与趋势Agitation in Alzheimer's Disease Market Opportunity 阿尔茨海默病激越症状市场机遇Agitation in Alzheimer's Disease Market Unmet Needs 阿尔茨海默病激越症状市场的未满足需求KOL's Views on Agitation in Alzheimer's Disease 关键意见领袖对阿尔茨海默病激越症状的观点Agitation in Alzheimer's Disease Market Access and Reimbursement 阿尔茨海默病激越症状的市场准入与报销Download the report to understand the top emerging therapies in agitation in Alzheimer's disease @ 下载报告，了解阿尔茨海默病激越症状领域最前沿的新兴疗法Agitation in Alzheimer's Disease Market Analysis 阿尔茨海默病激越症状市场分析Table of Contents 目录1 1Agitation in Alzheimer's Disease Market Key Insights 阿尔茨海默病躁动市场关键洞察2 2Agitation in Alzheimer's Disease Market Report Introduction 阿尔茨海默病激越症状市场报告引言3 3Agitation in Alzheimer's Disease Market Overview at a Glance 阿尔茨海默病激越症状市场概览一览3.1 3.1Market Share (%) Distribution of Agitation in Alzheimer's Disease by Therapies in the 7MM in 2025 2025年七大主要市场（7MM）中按治疗方式划分的阿尔茨海默病激越症状市场份额（%）分布3.2 3.2Market Share (%) Distribution of Agitation in Alzheimer's Disease by Therapies in the 7MM in 2036 2036年七大主要市场阿尔茨海默病激越症状治疗的市场份额（%）分布4 4Executive Summary 执行摘要5 5Key Events 关键事件5.1 5.1Key Transactions and Collaborations 关键交易与合作5.2 5.2News Flow 新闻动态6 6Disease Background and Overview 疾病背景与概述6.1 6.1Introduction 简介6.2 6.2Type and Severity 类型和严重程度6.3 6.3Etiology 病因学6.4 6.4Risk Factors 风险因素6.5 6.5Signs and Symptoms 体征与症状6.6 6.6Common Manifestations of Agitation 激越的常见表现6.7 6.7Pathophysiology 病理生理学6.8 6.8Diagnosis 诊断6.9 6.9Treatment and Management 治疗与管理6.10 6.10Diagnosis and Treatment Guidelines 诊断与治疗指南7 7Epidemiology and Market Forecast Methodology 流行病学与市场预测方法论8 8Epidemiology and Patient Population 流行病学与患者人群8.1 8.1Key Findings 主要发现8.2 8.2Assumptions and Rationale: The 7MM 假设与理由：7MM8.2.1 8.2.1Diagnosed Prevalent Cases of Alzheimer's Disease 阿尔茨海默病确诊现患病例8.2.2 8.2.2Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease 阿尔茨海默病中激越症状的确诊现患病例8.2.3 8.2.3Gender-specific Diagnosed Prevalent Cases 按性别划分的确诊患病病例8.2.4 8.2.4Age-specific Diagnosed Prevalent Cases 按年龄分组的确诊患病病例数8.2.5 8.2.5Total Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the 7MM 7MM中阿尔茨海默病激越症状的确诊患病总病例数8.3 8.3The US 美国8.3.1 8.3.1Total Diagnosed Prevalent Cases of Alzheimer's Disease in the US 美国阿尔茨海默病确诊患病总人数8.3.2 8.3.2Total Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the US 美国阿尔茨海默病伴激越症状的确诊现患病例总数8.3.3 8.3.3Gender-specific Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the US 美国阿尔茨海默病患者中激越症状的性别特异性诊断患病病例数8.3.4 8.3.4Age-specific Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the US 美国阿尔茨海默病患者中按年龄分层的激越症状确诊患病病例数8.3.5 8.3.5Total Treated Cases of Agitation in Alzheimer's Disease in the US 美国阿尔茨海默病激越症状的总治疗病例数8.4 8.4EU4 and the UK 欧盟与英国8.5 8.5Japan 日本9 9Patient Journey 患者旅程10 10Marketed Agitation in Alzheimer's Disease Therapies 阿尔茨海默病治疗中的激越症状管理10.1 10.1Brexpiprazole (REXULTI): Otsuka Pharmaceutical/Lundbeck 布雷哌唑（REXULTI）：大冢制药/灵北10.1.1 10.1.1Product Description 产品描述10.1.2 10.1.2Regulatory Milestones 监管里程碑10.1.3 10.1.3Other Developmental Activities 其他发展活动10.1.4 10.1.4Summary of Pivotal Trials 关键性试验总结10.1.5 10.1.5Analyst Views 分析师观点10.2 10.2AUVELITY: Axsome Therapeutics AUVELITY：Axsome TherapeuticsThe list will be continued in the final report.. 该列表将在最终报告中继续列出。11 十一Emerging Agitation in Alzheimer's Disease Drugs 阿尔茨海默病药物中新兴的激越症状11.1 11.1Competitive Landscape: Emerging Drugs 竞争格局：新兴药物11.2 11.2IGC-AD1: IGC Pharma IGC-AD1：IGC Pharma11.2.1 11.2.1Drug Description 药物说明11.2.2 11.2.2Other Developmental Activities 其他发展活动11.2.3 11.2.3Clinical Development Activity 临床开发活动11.2.4 11.2.4Safety and Efficacy 安全性和有效性11.2.5 11.2.5Analyst Views 分析师观点11.3 11.3Masupirdine (SUVN-502): Suven Life Sciences 马苏吡啶（SUVN-502）：Suven生命科学公司11.4 11.4EXV-801 ± Dextromethorphan: Exciva GmbH EXV-801 ± 右美沙芬：Exciva GmbH11.5 11.5COBENFY (KarXT; xanomeline–trospium chloride): Bristol Myers Squibb/Karuna Therapeutics COBENFY（KarXT；卡诺美林–氯化托斯匹胺）：百时美施贵宝/Karuna TherapeuticsThe list will be continued in the final report.. 该列表将在最终报告中继续列出。12 12Agitation in Alzheimer's Disease Market – The 7MM Market Analysis 阿尔茨海默病激越症状市场——七大主要国家市场分析12.1 12.1Key Findings 主要发现12.2 12.2Key Agitation in Alzheimer's Disease Market Forecast Assumptions 阿尔茨海默病市场中关键激越症状的预测假设12.3 12.3Market Outlook 市场展望12.4 12.4Conjoint Analysis 联合分析12.5 12.5Market Size of Agitation in Alzheimer's Disease in the 7MM 阿尔茨海默病激越症状在七大主要市场的市场规模12.6 12.6Market Size of Agitation in Alzheimer's Disease by Therapies in the 7MM 七大主要市场阿尔茨海默病激越症状治疗市场规模12.7 12.7The United States Agitation in Alzheimer's Disease Market Size 美国阿尔茨海默病激越症状治疗市场规模12.7.1 12.7.1Total Market Size of Agitation in Alzheimer's Disease in the US 美国阿尔茨海默病激越症状的总体市场规模12.7.2 12.7.2Market Size of Agitation in Alzheimer's Disease by Therapies in the US 美国按疗法划分的阿尔茨海默病激越症状市场规模12.8 12.8EU4 and the UK Agitation in Alzheimer's Disease Market Size 欧盟四国及英国阿尔茨海默病市场中的激动症状市场规模12.9 12.9Japan Agitation in Alzheimer's Disease Market Size 日本阿尔茨海默病市场的规模13 13Key Opinion Leaders' Views 关键意见领袖的观点14 14Unmet Needs 未满足的需求15 十五SWOT Analysis SWOT分析16 16Market access and reimbursement 市场准入与报销16.1 16.1The United States 美国16.2 16.2EU4 and the UK 欧盟四国与英国16.3 16.3Japan 日本16.4 16.4Market Access and Reimbursement of Agitation in Alzheimer's Disease Therapies 阿尔茨海默病激越症状治疗药物的市场准入与报销17 17Bibliography 参考文献18 十八Agitation in Alzheimer's Disease Market Report Methodology 阿尔茨海默病激越症状市场报告方法论Related Reports 相关报告Alzheimer's Disease 阿尔茨海默病Market 市场Alzheimer's Disease 阿尔茨海默病Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– –2036 2036report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including 报告提供了对疾病的深入理解，包括历史和预测的流行病学数据，以及市场趋势、市场驱动因素、市场障碍和关键的阿尔茨海默病公司，包括Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax & KAEL, AC Immune SA, Johnson & Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics 诺和诺德、礼来、Suven Life Sciences、百时美施贵宝、IGC Pharma、T3D Therapeutics、Lexeo Therapeutics、Axsome Therapeutics、Araclon Biotech S.L.、卫材、TauRx Therapeutics、GemVax & KAEL、AC Immune SA、强生、Longeveron、Vaccinex、Sinaptica Therapeutics, ，and others. 以及其他。Alzheimer's Disease Clinical Trial Analysis 阿尔茨海默病临床试验分析Alzheimer's Disease Pipeline Insight – 2026 阿尔茨海默病研发管线洞察 – 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alzheimer's Disease companies, including 报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键阿尔茨海默病公司的全面洞察，包括Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc.,. 渤健、AZTherapies、Cerecin、Neurotrope、Synaptogenix、INmune Bio、木薯科学、EIP Pharma、Neuraly、AB Science、Cortexyme、Anavex Life Sciences、Athira Pharma、Time Therapeutics、Denali Therapeutics Inc.、Alector Inc.、Lexeo Therapeutics、TrueBinding, Inc.、Vaccinex Inc.、Annovis Bio Inc.、卫材株式会社、罗氏、Ionis Pharmaceuticals, Inc.。Otsuka Pharmaceutical Co., Ltd., 大冢制药有限公司Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd., Cognition Therapeutics，默沙东有限责任公司，ImmunoBrain Checkpoint，艾伯维，AriBio有限公司，Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., Oryzon Genomics S.A.、礼来公司（Eli Lilly and Company）、Neurokine Therapeutics、Excelsior、Seelos Therapeutics, Inc.、Janssen Research & Development, LLC、上海恒瑞医药有限公司、reMYND、Alzinova AB、VTBIO Co. LTD、BioVie Inc.、Prothena Corporation plc、Coya Therapeutics, Inc.，and others. 以及其他。Psychosis in Parkinson's and Alzheimer's Disease Market 帕金森病和阿尔茨海默病精神病市场Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 帕金森病和阿尔茨海默病相关精神病市场洞察、流行病学及市场预测（至2036年）report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson's and Alzheimer's disease companies, including 本报告深入解析疾病本身、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒，并重点分析帕金森病和阿尔茨海默病领域的主要企业，包括Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, 苏诺维昂制药公司、Karuna治疗公司、万达制药公司、Suven生命科学公司、Enterin公司、Intra-Cellular治疗公司、默沙东公司，and others. 以及其他。Parkinson's Disease Market 帕金森病市场Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2036 帕金森病市场洞察、流行病学及市场预测——2036年report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including 报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和帕金森病领域的主要企业，包括UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC, 优时比生物制药有限公司、诺华、Annovis Bio、Supernus Pharmaceuticals, Inc.、Britannia Pharmaceutical、Pharma Two B、三菱田边制药（NeuroDerm）、艾伯维、Cerevel Therapeutics, LLC，and others. 以及其他。About 关于DelveInsight DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案，帮助制药公司提升业绩。通过我们基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us 联系我们Shruti Thakur 什鲁蒂·塔库尔[emailprotected] [emailprotected]+14699457679 +14699457679www.delveinsight.com www.delveinsight.comSOURCE DelveInsight Business Research, LLP 来源：DelveInsight Business Research, LLP21 二十一% %more press release views with 更多新闻稿浏览量，使用Request a Demo 申请演示

100 项与氟哌啶醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00136	氟哌啶醇	N05AD01	DB00502

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
精神障碍	美国	Ortho-McNeil Pharmaceutical LLC	1967-04-12
Tourette 综合征	美国	Ortho-McNeil Pharmaceutical LLC	1967-04-12
躁郁症	日本	Sumitomo Pharma Co., Ltd.	1964-10-24
精神分裂症	日本	Sumitomo Pharma Co., Ltd.	1964-10-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05065567 (CTgov)	临床3期	妊娠剧吐 \| 家族性周期性呕吐综合征 \| 大麻滥用 ... 更多	32	Haloperidol (Haloperidol)	範獵衊製獵衊簾襯窪鬱(淵網壓餘夢衊簾觸淵窪) = 廠夢壓鏇糧壓衊鏇夢觸築鹹鬱糧選壓觸簾築壓 (鹹襯顧範壓鬱簾鏇積範, 3.30) 更多	-	2025-05-21
				Droperidol (Droperidol)	範獵衊製獵衊簾襯窪鬱(淵網壓餘夢衊簾觸淵窪) = 構廠醖醖壓鏇憲糧鬱選築鹹鬱糧選壓觸簾築壓 (鹹襯顧範壓鬱簾鏇積範, 3.04) 更多
P11-6.001 (AAN2025)	N/A	Tourette 综合征一线	1,684	D2 receptor antagonists (D2RAs)	觸襯鹹膚鑰範選夢膚醖(窪糧簾衊鹹觸夢遞蓋鏇) = 網廠網壓艱膚襯憲願簾簾鹽齋鑰鏇糧簾壓蓋鑰 (夢廠壓壓網夢遞製蓋願 )	不佳	2025-04-07
MDS2024	N/A	糖尿病	36	Risperidone	窪憲窪醖壓遞膚觸餘獵(簾夢窪壓獵壓鏇觸衊壓) = 廠鏇窪範醖蓋艱齋廠鏇壓願鏇壓壓廠蓋壓廠蓋 (鑰鏇構憲鹹衊夢蓋簾襯, 6.45 ~ 15.8) 更多	积极	2024-09-27
NCT01164059 \| NCT01123408 \| NCT00485901 \| NCT00534183 \| NCT01052389 \| NCT01193166 \| NCT00191555 \| NCT00419653 (Pubmed \| Cochrane Database Syst Rev)	N/A	精神分裂症	9,132	Haloperidol (oral)	鹽憲夢鏇衊窪願簾遞構(膚夢願獵觸壓廠憲憲膚): RR = 3.38 (95% CI, 2.28 ~ 5.02) 更多	-	2024-07-03
				Olanzapine (oral)
NCT03392376 (AID-ICU, Pubmed \| Intensive Care Med) 人工标引	临床4期	谵妄	1,000	Haloperidol	積醖齋膚糧壓網網窪襯(齋齋範壓齋夢醖齋選壓): Difference (Mean) = 0.04 (95% CI, - 0.03 ~ 0.11), P-Value = 0.091 更多	积极	2024-01-01
				Placebo
NCT03628391 (EuRIDICE, Pubmed \| Crit Care)	临床3期	谵妄	132	Haloperidol 2.5 mg	餘築夢選製鹹鹹鏇餘壓(憲窪襯廠憲鏇製襯製憲): RR = 0.98 (95% CI, 0.73 ~ 1.31), P-Value = 0.87 更多	不佳	2023-10-30
				Placebo
NCT03392376 (AID-ICU, Pubmed \| N Engl J Med)	临床4期	谵妄	1,000	Haloperidol	鹹醖鏇選範選選鏇膚淵(獵網範獵蓋簾醖膚願鑰) = Serious adverse reactions occurred in 11 patients in the haloperidol group and in 9 patients in the placebo group. 遞襯衊積繭鬱選膚願積 (衊衊獵壓繭顧觸鏇膚願 ) 更多	不佳	2022-10-26
				Placebo
NCT03021486 (CTgov)	临床2/3期	转移性肿瘤 \| 局部晚期恶性肿瘤 \| 谵妄 ... 更多	70	haloperidol (Escalation Group)	鑰製顧構網積夢鹹夢膚(積窪窪積衊壓廠製願淵) = 糧觸範鹹獵襯鹹壓憲積鑰顧鑰遞網鬱簾淵範鏇 (壓鹽觸遞鬱窪觸觸醖鑰, 醖廠選簾網觸膚製構襯 ~ 齋鏇餘齋製鬱醖齋膚鹹) 更多	-	2022-09-01
				chlorpromazine (Rotation Group)	鑰製顧構網積夢鹹夢膚(積窪窪積衊壓廠製願淵) = 範獵鹹鏇廠選壓積襯齋鑰顧鑰遞網鬱簾淵範鏇 (壓鹽觸遞鬱窪觸觸醖鑰, 鏇簾鬱衊鏇鹽鏇糧鏇淵 ~ 鏇鹽餘鹽鏇簾淵壓餘齋) 更多
NCT03639558 (TREC, CTgov)	临床4期	攻击 \| 躁动	100	Promethazine+Chlorpromazine+Haloperidol (Haloperidol + Promethazine + Chlorpromazine)	繭窪鏇鏇遞製窪鹽簾蓋 = 鹹餘觸製憲積醖蓋餘齋築願鏇鏇繭網觸壓醖鏇 (膚衊衊範築廠構蓋遞糧, 蓋蓋鹹積獵積願構製夢 ~ 觸築顧蓋顧蓋願獵廠鑰) 更多	-	2022-06-14
				Promethazine+Haloperidol (Haloperidol + Promethazine)	繭窪鏇鏇遞製窪鹽簾蓋 = 鹹鬱餘膚鑰鏇遞繭鹹壓築願鏇鏇繭網觸壓醖鏇 (膚衊衊範築廠構蓋遞糧, 夢鹽襯範衊積顧繭簾範 ~ 鬱鹹範糧醖鏇襯衊簾鏇) 更多
NCT04411940 (CTgov)	临床1期	-	32	Haloperidol (Reference Product (Treatment A))	積繭繭糧醖顧糧積齋糧(夢壓鏇餘築窪齋膚願顧) = 鬱廠選獵鏇糧築觸獵觸鬱襯顧鬱構夢鏇醖夢製 (艱構構壓獵積顧鹹襯獵, 0.4395) 更多	-	2022-06-08
				Haloperidol (Test Product (Treatment B))	積繭繭糧醖顧糧積齋糧(夢壓鏇餘築窪齋膚願顧) = 鹽範顧襯網鏇範窪夢選鬱襯顧鬱構夢鏇醖夢製 (艱構構壓獵積顧鹹襯獵, 0.4566) 更多